Moneycontrol PRO
HomeNewsBusinessMarketsAsian shares claw back some Omicron losses but risks loom large

Asian shares claw back some Omicron losses but risks loom large

U.S. stock indexes retreated more than 1% as positive COVID-19 case counts rose and President Joe Biden’s social spending and climate bill hit a significant setback.

December 21, 2021 / 08:42 IST

Asian stocks rose on Tuesday, shrugging off a bruising Wall Street session, as Chinese markets cheered Beijing’s push to help troubled property firms, although surging cases of the Omicron coronavirus variant persist as a worry for investors.

U.S. stock indexes retreated more than 1% as positive COVID-19 case counts rose and President Joe Biden’s social spending and climate bill hit a significant setback.

The negative mood brightened somewhat in early Asian hours with U.S. stock futures up and some assets battered in Monday’s selling finding buyers, although volumes were thin heading into end-of-year holidays.

MSCI’s broadest index of Asia-Pacific shares outside Japan was up 0.4%. Japan’s Nikkei rose 1.79% as investors bought into Monday’s heavy selloff while Australian stocks were up 0.47%.

While the global shares rout appeared to pause, investors are still concerned about Omicron risks.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"COVID remains a threat to the global economy. Initial evidence suggests the Omicron variant is more transmissible but results in less severe illness compared to previous variants," economists at CBA wrote in a note.

In China, the blue-chip CSI300 index was 0.37% higher while the Shanghai Composite Index rose 0.46%, with real estate developers leading gains.

The moves higher come as China reportedly urged large private and state-owned property companies to acquire real estate projects from troubled developers to reduce risks that mounting debt piles will destabilise the economy.

Hong Kong’s Hang Seng index opened up 0.56%.

On Monday, the Dow Jones Industrial Average fell 1.23%, the S&P 500 1.14% and the Nasdaq Composite dropped 1.24%.

Europe’s main indexes also sold off after British Prime Minister Boris Johnson said he would tighten coronavirus curbs if needed, after the Netherlands began a fourth lockdown and others in the region considered Christmas restrictions.

Early Tuesday, the dollar index, which tracks the greenback against a basket of currencies of other major trading partners, was down at 96.512.

The yield on benchmark 10-year Treasury notes rose to 1.4225% compared with its U.S. close of 1.419% on Monday. The two-year yield, which rises with traders’ expectations of higher Fed fund rates, touched 0.6297% compared with a U.S. close of 0.63%.

Oil prices started to recover from concerns the spread of the Omicron variant would crimp demand for fuel and signs of improving supply.

U.S. crude ticked up 0.71% to $69.1 a barrel. Brent crude rose to $71.9 per barrel.

Gold was slightly higher. Spot gold was traded at $1791.32 per ounce.

Reuters
first published: Dec 21, 2021 08:43 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347